Brian’s Story: Finding a Treatment for Type 1 Gaucher
Brian Berman is president and chief executive officer of the National Gaucher Foundation (NGF). Diagnosed at the age of 4 with Type 1 Gaucher disease after suffering critical and worsening symptoms, Mr. Berman’s initial prognosis was grim. His parents refused to watch their son die without a fight. They found Dr. Roscoe Brady, who was then leading groundbreaking research on Gaucher disease treatment. Mr. Berman, an ideal clinical trial candidate, became the first person in the world to successfully receive enzyme replacement therapy for Gaucher disease.
I hope you appreciated this article. Before you go, I’d like to ask you to please support the Forward’s award-winning journalism this Passover.
In this age of misinformation, our work is needed like never before. We report on the news that matters most to American Jews, driven by truth, not ideology.
At a time when newsrooms are closing or cutting back, the Forward has removed its paywall. That means for the first time in our 126-year history, Forward journalism is free to everyone, everywhere. With an ongoing war, rising antisemitism, and a flood of disinformation that may affect the upcoming election, we believe that free and open access to Jewish journalism is imperative.
Readers like you make it all possible. Right now, we’re in the middle of our Passover Pledge Drive and we still need 300 people to step up and make a gift to sustain our trustworthy, independent journalism.
Make a gift of any size and become a Forward member today. You’ll support our mission to tell the American Jewish story fully and fairly.
— Rachel Fishman Feddersen, Publisher and CEO
Join our mission to tell the Jewish story fully and fairly.
Only 300 more gifts needed by April 30